PureTech Health plc PRTCY
Set alert
At close · Oct 30
- YTD
- -5.53%
- 1 year
- -7.53%
- Open
- 15.71
- Prev close
- 15.31
- Mkt cap
- 382.65M
- Vol
- 100
- Avg vol
- 2.41K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 15.71
- High
- 15.71
News
2 days ago businesswire.com
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
BOSTON--(BUSINESS WIRE)--PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category.
6 days ago businesswire.com
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
BOSTON--(BUSINESS WIRE)--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026.
1 week ago businesswire.com
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
BOSTON--(BUSINESS WIRE)--PureTech Announces Presentation of Phase 1b Results for LYT-200 in R/R High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia at ESMO 2026.
1 month ago seekingalpha.com
PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript
PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript
1 month ago marketbeat.com
PureTech Health H1 Earnings Call Highlights
PureTech Health NASDAQ: PRTC outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory…
1 month ago businesswire.com
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into…
2 months ago businesswire.com
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress.